-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.

Zhitongcaijing·09/09/2026 06:33:57
Listen to the news
Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.